 BOSTON--BUSINESS WIRE--Verastem Oncology Nasdaq:VSTM, a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced a mini oral presentation highlighting updated data from the ongoing investigator-sponsored Phase 12 FRAME study. The FRAME study, led by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, is investigating VS-6766, Verastems RAFMEK inhibitor, in combination with defactinib, its FAK inhibitor, in 